Avidity Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Avidity Biosciences has a total shareholder equity of $1.5B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.6B and $137.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.59b |
| Equity | US$1.50b |
| Total liabilities | US$137.39m |
| Total assets | US$1.64b |
Recent financial health updates
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01
Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Recent updates
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Avidity Biosciences: Risks And Potential
Dec 09We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Nov 30Financial Position Analysis
Short Term Liabilities: RNA's short term assets ($1.6B) exceed its short term liabilities ($91.3M).
Long Term Liabilities: RNA's short term assets ($1.6B) exceed its long term liabilities ($46.1M).
Debt to Equity History and Analysis
Debt Level: RNA is debt free.
Reducing Debt: RNA has no debt compared to 5 years ago when its debt to equity ratio was 12.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RNA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: RNA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 37.5% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avidity Biosciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |